In T-cells derived from ruxolitinib-treated MPN patients, CD69 expression and proliferative capacity were almost abrogated in CD8+ and significantly impaired in CD4+ T cells, confirming that JAK1/2 inhibitors significantly decrease T-cell reactivity and proliferation in vivo. This evidence concerns the gene CD4 and myeloproliferative neoplasm.